← Back to Home

A New Option to Prevent Colon Cancer Recurrence After Surgery: FDA Approves Tecentriq Plus Chemotherapy

For stage III DNA mismatch repair-deficient colon cancer, adding immunotherapy to postoperative chemotherapy improved the three-year disease-free survival rate by about 10 percentage points. The new approval brings treatment into an earlier setting, but also comes with more severe adverse events. Whether it extends overall survival remains to be determined through follow-up.

By SURL BioNews

After tumor removal, colon cancer treatment still faces a challenge: reducing the chance that the cancer will return. On October 8, the U.S. Food and Drug Administration (FDA) approved the immunotherapy drug atezolizumab (brand name Tecentriq) in combination with chemotherapy as postoperative adjuvant treatment for stage III DNA mismatch repair-deficient (dMMR) colon cancer, adding an option for this group of patients defined by their tumors’ molecular characteristics.

The intravenous formulation approved for this use is indicated for patients aged two years and older, in combination with fluoropyrimidines and oxaliplatin. Tecentriq Hybreza, a subcutaneous formulation containing hyaluronidase, was also approved for patients aged 12 years and older who weigh at least 40 kilograms. Treatment consists of six months of immunotherapy plus chemotherapy, followed by six months of immunotherapy alone; it is stopped earlier if the disease recurs or unacceptable toxicity develops.

This treatment targets a feature of cancer cells’ ability to repair errors in DNA replication. When the mismatch repair system fails, tumors tend to accumulate mutations and are often associated with high microsatellite instability (MSI-H), producing abnormal proteins that may be recognized by the immune system. Atezolizumab blocks the immune-suppressing signals transmitted by PD-L1, helping immune cells fight tumors. This approval brings that strategy into the treatment phase after complete tumor removal, with the aim of reducing recurrence.

The phase III ATOMIC trial supporting the approval enrolled 712 patients, all with stage III dMMR colon cancer whose tumors had been completely resected. They were randomly assigned to receive mFOLFOX6 chemotherapy or the same chemotherapy with atezolizumab added, followed by continued immunotherapy. mFOLFOX6 consists of fluorouracil, leucovorin, and oxaliplatin. The trial used a multicenter, open-label design, with disease-free survival as its primary endpoint—the length of time patients remain alive without disease recurrence.

At a median follow-up of 40.9 months, the three-year disease-free survival rate was 86.3% in the combination treatment group and 76.2% in the chemotherapy-only group, a difference of 10.1 percentage points. The FDA reported a hazard ratio for recurrence or death of 0.50 (95% confidence interval, 0.35 to 0.73; P = 0.0001), representing an approximately halved relative risk of these events during follow-up, rather than a 50-percentage-point reduction in each patient’s probability of recurrence. Median disease-free survival had not yet been reached in either group.

The improvement in efficacy also came with a greater treatment burden. The trial publication reported grade 3–4 adverse events in 84.1% of the combination group and 71.9% of the chemotherapy group; the nursing professional report referenced here indicated that the difference was driven mainly by neutropenia. The FDA also noted that the drug’s warnings include immune-mediated adverse reactions and infusion-related reactions. Overall survival data remain immature, so the current evidence supports improved disease-free survival but does not yet establish that patients live longer.

The scope of the approval and the limits of the trial evidence also need to be understood together: of the 712 participants, 711 were adults and only one was a child, leaving very limited direct clinical evidence in children. ATOMIC also compared the addition of immunotherapy to chemotherapy; it did not demonstrate that immunotherapy can replace chemotherapy. This development establishes a new postoperative treatment option for a specific molecular subtype, while its long-term survival benefit and treatment burden remain to be clarified through further follow-up.

References

  1. FDA
  2. CancerNetwork
  3. OncLive
  4. Oncology Nursing News